Trends - Novartis - Business Recorder

Novartis

Novartis raises annual sales guidance until 2028

FRANKFURT: Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028,...

Published 21 Nov, 2024 11:21am

Business & Finance

Novartis lifts 2024 guidance for third time on wider use of its drugs

FRANKFURT: Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider...

Published 29 Oct, 2024 12:34pm

Business & Finance

Sanofi MS drug tolebrutinib misses goal in relapsing disease trials

Sanofi’s most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to...

Published 02 Sep, 2024 12:36pm

World

Novartis aims for 5% annual sales growth through 2027

FRANKFURT: Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income...

Published 28 Nov, 2023 12:50pm

Business & Finance

Novartis to buy Chinook for up to $3.5bn in boost to late-stage pipeline

BERN: Novartis has agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to $3.5 billion to boost...

Published 19 Jun, 2023 06:54am

World

Novartis raises year forecast after sales boost

ZURICH: Pharmaceutical giant Novartis said Tuesday it was increasing its full-year sales and profits outlook after...

Published 25 Apr, 2023 12:45pm

Business & Finance

Novartis net profit down in Q3 amid restructuring

ZURICH: Swiss pharmaceutical giant Novartis on Tuesday reported a sharp drop in net profits in the third quarter,...

Published 25 Oct, 2022 01:02pm

Business & Finance

Novartis to save at least $1bn by 2024 thanks to simplified structure

ZURICH: Novartis said on Monday it was integrating its pharmaceuticals and oncology units into an innovative...

Published 04 Apr, 2022 12:47pm

Business & Finance

Novartis suspends some business activities in Russia

GENEVA: Swiss drugmaker Novartis said on Tuesday it was suspending capital investments, media advertising, and other...

Published 22 Mar, 2022 01:29pm

Business & Finance

Novartis Q4 core operating income gains 9%

FRANKFURT: Novartis reported fourth-quarter core operating income gained 9% as higher drug sales offset in increase...

Published 02 Feb, 2022 11:33am

World

Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners

ZURICH: Novartis said it will license in a new drug it has been developing with Molecular Partners to treat ...

Published 10 Jan, 2022 12:19pm

World

Novartis sees strong interest in Sandoz generics unit

ZURICH: Novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals...

Published 12 Dec, 2021 04:19am

Business & Finance

Novartis CEO says Sandoz attracting interest

ZURICH: Novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buyers,...

Published 10 Dec, 2021 11:45am

Business & Finance

Roche buys back voting rights from rival Novartis for $20.7bn

ZURICH: Novartis AG, a shareholder in Roche for more than 20 years, said on Thursday the two Swiss drugmakers had...

Published 04 Nov, 2021 02:13pm

Business & Finance

Novartis sells its Roche stake to Roche for $20.7bn

ZURICH: Novartis AG, a shareholder in Roche for more than 20 years, said on Thursday the two Swiss drugmakers had...

Published 04 Nov, 2021 11:47am

Business & Finance

Novartis extends deal to make Pfizer/BioNTech vaccines

ZURICH: Novartis has agreed to expand its fill-and-finish support for the Pfizer/BioNTech COVID-19 vaccine by using...

Published 21 Oct, 2021 11:15am

Business & Finance

Novartis to launch new Zolgensma trial after FDA lifts restriction

Novartis said it March it was laying off 400 people and closing a US gene therapy location as sales momentum for Zolgensma stalled last year

Updated 03 Aug, 2021 10:54am

Business & Finance

Novartis weighs entry into mRNA technology

Many companies, including Novartis, had withdrawn from antiviral and antibacterial research

Published 01 Jul, 2021 11:05am

World

Pfizer asks Swiss OK for COVID-19 vaccine for children 12 to 15

"Swissmedic will review the application in the rolling procedure. Pfizer can submit the latest data continuously without having to wait for the conclusive results from the clinical studies," the watchdog said on its website.

Published 07 May, 2021 08:17pm

Business & Finance

Novartis pushes back UK cholesterol study's end to 2026 on COVID disruption

In January 2020, Novartis struck a deal with the National Health Service to use its data to find patients at risk of heart disease for whom conventional treatment had failed. They are due to get Leqvio, which targets "bad cholesterol" that can cause heart attacks and strokes.
"With the impact of COVID in the UK, recruitment has been challenging," said John Tsai, Novartis's head of drug development, adding that recruitment is now "starting to get back on track".

Published 27 Apr, 2021 08:45pm

Business & Finance

Novartis profits slide in Q1 on weak generic drugs

At $2 billion (1.7 billion euros), the bottom line fell 5.0 percent year-on-year in January-March, even as revenues grew 1.0 percent, to $12.4 billion.

Published 27 Apr, 2021 04:32pm

Business & Finance

CureVac teams up with Swiss contract drugmaker Celonic to boost COVID-19 vaccine output

Celonic plans to manufacture the mRNA molecules that make up the vaccine, with up to 50 million doses expected by the end of 2021, the companies said.
The vaccine candidate, CVnCoV, whose late-stage trials began in December, will be produced at Celonic's facility in Heidelberg, Germany.

Published 30 Mar, 2021 06:53pm

Business & Finance

Novartis's bid to re-purpose inflammation drug Ilaris takes another hit

The drug, known generically as canakinumab and long approved to treat juvenile arthritis and rare Mediterranean fever, last year failed to help patients suffering from COVID-19 respiratory distress.
While the results were disappointing, "these data give us valuable insights into IL-1 inhibition," said John Tsai.

Updated 09 Mar, 2021 09:31pm

World

Novartis' canakinumab doesn't meet primary endpoint in phase III study

The canakinumab development program continues with two phase III non-small cell lung cancer clinical trials ongoing in first-line and adjuvant settings.

Published 09 Mar, 2021 12:40pm

Business & Finance

Novartis deal bolsters CureVac's vaccine contractor line-up

Other partners include Bayer, GSK, Fareva, Rentschler.
Novartis site to come on-stream in summer of 2021.
Novartis to make up to 50 mln doses this yr, more next year.

Published 04 Mar, 2021 07:17pm

Business & Finance

Swiss drugmaker Novartis to help make Pfizer-Biontech COVID-19 vaccine

Three vaccines from Western companies Pfizer-Biontech, AstraZeneca and Moderna have been approved by regulators.
Novartis has been mobilizing on multiple fronts to support the global pandemic response.

Published 29 Jan, 2021 05:15pm

Business & Finance

Novartis in talks on helping make COVID-19 vaccines, tests

Novartis Technical Operations is currently exploring ways in which we can collaborate with our partners in the industry.
We are currently in discussions with several companies with a view to supporting the manufacturing of vaccines and components for tests for COVID-19, and we will share details as soon as possible.

Published 28 Jan, 2021 07:07pm

Business & Finance

Swiss pharma giant Novartis posts higher 2020 profit

Sales edged up 3.0 percent to $48.7 billion, the company said in a statement.

Published 26 Jan, 2021 05:58pm

Business & Finance

Novartis buys neuroscience company Cadent for up to $770mn

Novartis said the acquisition added two new clinical stage programs to its neuroscience portfolio, one for schizophrenia and the other for movement disorders.

Published 17 Dec, 2020 12:37pm

Business & Finance

Trial fails of ruxolitinib in COVID-19: Novartis

The trial also did not show relevant benefit for other endpoints including mortality rate by day 29 and time to recovery, it said on Monday.

Published 14 Dec, 2020 12:20pm

Forex
World
Commodity

Currency	Rate
USD PKR Interbank Selling / Jan 1	277.92
USD PKR Interbank Buying / Jan 1	277.72
USD to Japanese Yen / Jan 1	150.01
USD to Swiss Franc / Jan 1	0.89
Pound Sterling to USD / Jan 1	1.27

Stock	Volume
India Sensex / Jan 1	80,853.10
Tokyo Nikkei / Jan 1	39,248.86
Hang Seng / Jan 1	19,694.44
FTSE 100 / Jan 1	8,345.09
Germany DAX 30 / Jan 1	20,011.64

Item	Value
Petrol/Litre / Jan 1	252.10
Crude Oil USD/Barrel / Jan 1	68.37
Karachi Cotton PKR/37.32 KG / Jan 1	17,685
Gold Spot USD/Ounce / Jan 1	2,645.88
Diesel/Litre / Jan 1	258.43

Gainers
Losers
Leaders

Stock	Price
786 Invest Ltd / Dec 3 786 Investments Limited(786)	7.30 ▼ 0.00 (0.00%)
AL-Abbas Sugar / Dec 3 Al-Abbas Sugar Mills Limited(AABS)	630 ▼ 0.00 (0.00%)
Agro Allianz / Dec 3 Agro Allianz Limited(AAL)	16 ▼ 0.00 (0.00%)
AL-Abid Silk / Dec 3 Al-Abid Silk Mills Limited(AASM)	3.49 ▼ 0.00 (0.00%)
Ali Asghar / Dec 3 Ali Asghar Textile Mills Limited(AATM)	67.69 ▼ 0.00 (0.00%)
Allied Bank / Dec 3 Allied Bank Limited(ABL)	150 ▼ 0.00 (0.00%)
Abbott Lab. / Dec 3 Abbott Laboratories (Pakistan) Limited(ABOT)	1,118.68 ▼ 0.00 (0.00%)
Abson Ind. / Dec 3 Abson Industries Limited(ABSON)	2.50 ▼ 0.00 (0.00%)
Alfalah ETF. / Dec 3 Alfalah Consumer Index ETF.(ACIETF)	13.14 ▼ 0.00 (0.00%)

Stock	Price
786 Invest Ltd / Dec 3 786 Investments Limited(786)	7.30 ▲ 0.00 (0.00%)
AL-Abbas Sugar / Dec 3 Al-Abbas Sugar Mills Limited(AABS)	630 ▲ 0.00 (0.00%)
Agro Allianz / Dec 3 Agro Allianz Limited(AAL)	16 ▲ 0.00 (0.00%)
AL-Abid Silk / Dec 3 Al-Abid Silk Mills Limited(AASM)	3.49 ▲ 0.00 (0.00%)
Ali Asghar / Dec 3 Ali Asghar Textile Mills Limited(AATM)	67.69 ▲ 0.00 (0.00%)
Allied Bank / Dec 3 Allied Bank Limited(ABL)	150 ▲ 0.00 (0.00%)
Abbott Lab. / Dec 3 Abbott Laboratories (Pakistan) Limited(ABOT)	1,118.68 ▲ 0.00 (0.00%)
Abson Ind. / Dec 3 Abson Industries Limited(ABSON)	2.50 ▲ 0.00 (0.00%)
Alfalah ETF. / Dec 3 Alfalah Consumer Index ETF.(ACIETF)	13.14 ▲ 0.00 (0.00%)

Stock	Volume
WorldCall Telecom / Dec 3 Worldcall Telecom Limited(WTL)	213,514,857 ▲ 0.00
Cnergyico PK / Dec 3 Cnergyico PK Limited(CNERGY)	196,907,321 ▲ 0.00
Fauji Foods Ltd / Dec 3 Fauji Foods Limited(FFL)	68,325,507 ▲ 0.00
K-Electric Ltd. / Dec 3 K-Electric Limited(KEL)	66,212,972 ▲ 0.00
Sui South Gas / Dec 3 Sui Southern Gas Company Limited(SSGC)	65,264,278 ▲ 0.00
B.O.Punjab / Dec 3 The Bank of Punjab(BOP)	61,288,845 ▲ 0.00
Hascol Petrol / Dec 3 Hascol Petroleum Limited(HASCOL)	49,268,731 ▲ 0.00
Pak Int.Bulk / Dec 3 Pakistan International Bulk Terminal(PIBTL)	46,902,495 ▲ 0.00
Fauji Cement / Dec 3 Fauji Cement Company Limited(FCCL)	31,910,059 ▲ 0.00

Markets →

Budget 2024-25: income tax calculator for FY25

Novartis

Most Popular